{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:26:00Z","timestamp":1787851560512,"version":"build-2784847793"},"reference-count":63,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Hot-melt extrusion (HME) is a scalable pharmaceutical technology increasingly relevant to flexible manufacturing, including small-batch production, personalized dosage-form development, and potential use in pharmacy compounding. When translated into compounding practice, however, HME introduces a risk that routine quality-control methods available in pharmacies may be insufficient to reliably assess the stability of extrusion-based preparations. Methods: Granules containing 50% (w\/w) darunavir were prepared by HME at 70 and 90 \u00b0C using a previously developed polymeric premix. Samples were stored for 24 months under ambient conditions. During storage, routine quality attributes were evaluated, including appearance, particle size distribution, loss on drying, disintegration time, content uniformity, and assay. Solid-state changes were investigated using differential scanning calorimetry (DSC) and X-ray diffraction (XRD), with a reference PEG-associated darunavir sample prepared and characterized for comparative analysis. Changes in drug release and darunavir content were assessed by dissolution testing and HPLC analysis, respectively. Results: Granules produced at both extrusion temperatures retained acceptable routine quality attributes throughout the 24-month storage period. No substantial changes were detected by visual inspection, pharmacopoeial tests, or UV assay. However, DSC revealed a new thermal event after storage, while XRD showed the formation of a new crystalline phase. Comparison with the reference PEG-associated sample supported the assignment of this phase as a PEG-associated crystalline phase of darunavir. Importantly, this transformation occurred even though the routine quality attributes evaluated in pharmacy compounding practice remained unchanged. Dissolution profiles differed between samples tested immediately after preparation and after long-term storage, with a more pronounced overall difference for granules produced at 90 \u00b0C, whereas HPLC confirmed comparable darunavir content in all investigated samples. Discussion: Our results show that routine compounding quality control can meet conventional acceptance criteria while failing to detect API solid-state changes in the investigated HME-derived system. In the PEG-containing matrix, amorphous darunavir undergoes storage-induced crystallization, forming a PEG-associated crystalline phase consistent with its known affinity for polyol-containing media. Conclusions: Acceptable routine quality attributes do not necessarily reflect the solid-state stability of APIs in HME-based formulations. These results highlight the need for solid-state risk assessment when developing extrusion-based systems intended for pharmacy compounding and other personalized manufacturing models in which routine quality control may not include advanced solid-state characterization.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091079","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:47:13Z","timestamp":1787849233000},"page":"1079","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hidden Solid-State Transformation of Darunavir in Low-Temperature Hot-Melt-Extruded Granules: Implications for Pharmacy Compounding and Routine Quality Control"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-9615","authenticated-orcid":false,"given":"Mark","family":"Mandrik","sequence":"first","affiliation":[{"name":"A.P. Nelyubin Institute of Pharmacy, Sechenov First Moscow State Medical University, 8-2 Trubetskaya str., 119991 Moscow, Russia"},{"name":"A.V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, Leninsky pr. 29, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-1630","authenticated-orcid":false,"given":"Veronika","family":"Makarova","sequence":"additional","affiliation":[{"name":"A.V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, Leninsky pr. 29, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5919-1866","authenticated-orcid":false,"given":"Ludmila","family":"Korol","sequence":"additional","affiliation":[{"name":"A.P. Nelyubin Institute of Pharmacy, Sechenov First Moscow State Medical University, 8-2 Trubetskaya str., 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-9909","authenticated-orcid":false,"given":"Ivan","family":"Sadkovskii","sequence":"additional","affiliation":[{"name":"A.P. Nelyubin Institute of Pharmacy, Sechenov First Moscow State Medical University, 8-2 Trubetskaya str., 119991 Moscow, Russia"},{"name":"A.V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, Leninsky pr. 29, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-2988","authenticated-orcid":false,"given":"Ivan","family":"Krasnyuk","sequence":"additional","affiliation":[{"name":"A.P. Nelyubin Institute of Pharmacy, Sechenov First Moscow State Medical University, 8-2 Trubetskaya str., 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-7906","authenticated-orcid":false,"given":"Sergey","family":"Antonov","sequence":"additional","affiliation":[{"name":"A.V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences, Leninsky pr. 29, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1208\/s12249-024-02749-2","article-title":"Hot-Melt Extrusion: From Theory to Application in Pharmaceutical Formulation\u2014Where Are We Now?","volume":"25","author":"Patil","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijpharm.2017.10.056","article-title":"Melt extrusion with poorly soluble drugs\u2014An integrated review","volume":"535","author":"Repka","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1208\/s12249-020-01713-0","article-title":"Developing HME-Based Drug Products Using Emerging Science: A Fast-Track Roadmap from Concept to Clinical Batch","volume":"21","author":"Paudel","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40005-024-00684-9","article-title":"Advancements of hot-melt extrusion technology to address unmet patient needs and pharmaceutical quality aspects","volume":"55","author":"Park","year":"2025","journal-title":"J. Pharm. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijpharm.2016.05.036","article-title":"Hot-melt extruded filaments based on pharmaceutical grade polymers for 3D printing by fused deposition modeling","volume":"509","author":"Melocchi","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/10837450.2018.1433208","article-title":"Formulation development and process analysis of drug-loaded filaments manufactured via hot-melt extrusion for 3D-printing of medicines","volume":"23","author":"Korte","year":"2018","journal-title":"Pharm. Dev. Technol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijpharm.2016.12.049","article-title":"Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets","volume":"519","author":"Zhang","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.addr.2021.02.006","article-title":"Coupling hot melt extrusion and fused deposition modeling: Critical properties for successful performance","volume":"172","author":"Bandari","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"120501","DOI":"10.1016\/j.ijpharm.2021.120501","article-title":"3D printing in personalized drug delivery: An overview of hot-melt extrusion-based fused deposition modeling","volume":"600","author":"Dumpa","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Arany, P., Papp, \u00c1., Nemes, D., Feh\u00e9r, P., Ujhelyi, Z., and B\u00e1cskay, I. (2026). Quality by Design Approach for Hot-Melt Extrusion Coupled Fused Deposition Modeling (HME-FDM) 3D Printing: A Systematic Review. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18050569"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jconrel.2020.10.056","article-title":"Fused Deposition Modeling (FDM), the new asset for the production of tailored medicines","volume":"330","author":"Cailleaux","year":"2021","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.tips.2018.02.006","article-title":"3D Printing Pharmaceuticals: Drug Development to Frontline Care","volume":"39","author":"Trenfield","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s43441-021-00354-0","article-title":"Quality of FDM 3D Printed Medicines for Pediatrics: Considerations for Formulation Development, Filament Extrusion, Printing Process and Printer Design","volume":"56","author":"Quodbach","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mandrik, M., Makarova, V., Korol, L., Krasnyuk, I., and Antonov, S. (2026). Rational Design of Multicomponent Polymeric Systems Based on a Transient Plasticization Window for Hot-Melt Extrusion. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18060667"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"104011","DOI":"10.1016\/j.drudis.2024.104011","article-title":"Premix technologies for drug delivery: Manufacturing, applications, and opportunities in regulatory filing","volume":"29","author":"Ashokbhai","year":"2024","journal-title":"Drug Discov. Today"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105655","DOI":"10.1016\/j.ejps.2020.105655","article-title":"Quality-by-design in hot melt extrusion based amorphous solid dispersions: An industrial perspective on product development","volume":"158","author":"Butreddy","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kyeremateng, S.O., Voges, K., Dohrn, S., Sobich, E., Lander, U., Weber, S., Gessner, D., Evans, R.C., and Degenhardt, M. (2022). A Hot-Melt Extrusion Risk Assessment Classification System for Amorphous Solid Dispersion Formulation Development. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051044"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Uriel, M., Marro, D., and G\u00f3mez Rinc\u00f3n, C. (2023). An Adequate Pharmaceutical Quality System for Personalized Preparation. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030800"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13181-020-00814-3","article-title":"Pharmaceutical Compounding: A History, Regulatory Overview, and Systematic Review of Compounding Errors","volume":"17","author":"Watson","year":"2021","journal-title":"J. Med. Toxicol."},{"key":"ref_20","unstructured":"U.S. Food and Drug Administration (2026, June 10). Draft Guidance for Industry. Current Good Manufacturing Practice\u2014Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act: Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/current-good-manufacturing-practice-guidance-human-drug-compounding-outsourcing-facilities-under."},{"key":"ref_21","unstructured":"National Association of Pharmacy Regulatory Authorities (2018). Guidance Document for Pharmacy Compounding of Non-Sterile Preparations, National Association of Pharmacy Regulatory Authorities. Available online: https:\/\/www.napra.ca\/publication\/guidance-document-for-pharmacy-compounding-of-non-sterile-preparations."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Secretan, P.-H., Annereau, M., and Do, B. (2025). A Risk-Based Framework for Hospital Compounding: Integrating Degradation Mechanisms and Predictive Toxicology. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17091202"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Iyer, R., Petrovska Jovanovska, V., Berginc, K., Jakli\u010d, M., Fabiani, F., Harlacher, C., Huzjak, T., and Sanchez-Felix, M.V. (2021). Amorphous Solid Dispersions (ASDs): The Influence of Material Properties, Manufacturing Processes and Analytical Technologies in Drug Product Development. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101682"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.xphs.2016.06.017","article-title":"Effect of Temperature and Moisture on the Physical Stability of Binary and Ternary Amorphous Solid Dispersions of Celecoxib","volume":"106","author":"Xie","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1021\/acs.molpharmaceut.7b00492","article-title":"Impact of Polymer Type and Relative Humidity on the Long-Term Physical Stability of Amorphous Solid Dispersions","volume":"14","author":"Lehmkemper","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1021\/acs.molpharmaceut.3c00526","article-title":"Crystallinity: A Complex Critical Quality Attribute of Amorphous Solid Dispersions","volume":"20","author":"Moseson","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2017.03.002","article-title":"Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals","volume":"117","author":"Healy","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Grell, T., Barbero, M., Pattarino, F., Giovenzana, G.B., and Colombo, V. (2021). Solvatomorphism of Moxidectin. Molecules, 26.","DOI":"10.3390\/molecules26164869"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.molpharmaceut.6b00763","article-title":"Long-Term Physical Stability of PVP- and PVPVA-Amorphous Solid Dispersions","volume":"14","author":"Lehmkemper","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41467-025-67806-1","article-title":"Phase diagrams of pharmaceutical solvates from mechanochemistry","volume":"17","author":"Theodosiou","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1021\/acs.cgd.0c00751","article-title":"Solid-State Characterization and Role of Solvent Molecules on the Crystal Structure, Packing, and Physiochemical Properties of Different Quercetin Solvates","volume":"20","author":"Klitou","year":"2020","journal-title":"Cryst. Growth Des."},{"key":"ref_32","first-page":"100834","article-title":"Advances in the development of amorphous solid dispersions: The role of polymeric carriers","volume":"18","author":"Zhang","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Jurczak, E., Mazurek, A.H., Szeleszczuk, \u0141., Pisklak, D.M., and Zieli\u0144ska-Pisklak, M. (2020). Pharmaceutical Hydrates Analysis\u2014Overview of Methods and Recent Advances. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12100959"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/acs.cgd.3c00057","article-title":"Stability and Mechanical Properties of Darunavir Isostructural Solvates: An Experimental and Computational Study","volume":"23","author":"Yu","year":"2023","journal-title":"Cryst. Growth Des."},{"key":"ref_35","unstructured":"Kamat, A.G., Ganala, N.T., Boddu, V.B., Koilpillai, J.P., and Meenaakshisunderam, S. (2017). Solvates of Darunavir. (US9643976B2), U.S. Patent."},{"key":"ref_36","unstructured":"Royal Society of Chemistry (2026, June 13). The Merck Index Online, Darunavir, Monograph M4099. Available online: https:\/\/merckindex.rsc.org\/monographs\/m4099."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejpb.2018.06.021","article-title":"Amorphous Solid Dispersions of Darunavir: Comparison Between Spray Drying and Electrospraying","volume":"130","author":"Smeets","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10337-022-04226-z","article-title":"Identification, Isolation, and Structural Characterization of Novel Forced Degradation Products of Darunavir Using Advanced Analytical Techniques Like UPLC-MS, Prep-HPLC, HRMS, NMR, and FT-IR Spectroscopy","volume":"86","author":"Modini","year":"2023","journal-title":"Chromatographia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/10837450.2010.508077","article-title":"800 mg Darunavir Tablets Prepared by Hot Melt Extrusion","volume":"16","author":"Thommes","year":"2011","journal-title":"Pharm. Dev. Technol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Makarova, V., Mandrik, M., and Antonov, S. (2025). Laser Microinterferometry for API Solubility and Phase Equilibria: Darunavir as a Case Example. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17070875"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Shi, Q., Chen, H., Wang, Y., Wang, R., Xu, J., and Zhang, C. (2022). Amorphous Solid Dispersions: Role of the Polymer and Its Importance in Physical Stability and In Vitro Performance. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081747"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"119925","DOI":"10.1016\/j.ijpharm.2020.119925","article-title":"Physical Stability of Amorphous Pharmaceutical Solids: Nucleation, Crystal Growth, Phase Separation and Effects of the Polymers","volume":"590","author":"Shi","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_43","first-page":"117","article-title":"Development and Validation of UV-Spectrophotometry Method for Quantitative Determination of Amorphous Darunavir","volume":"13","author":"Mandrik","year":"2024","journal-title":"Drug Dev. Regist."},{"key":"ref_44","unstructured":"U.S. Food and Drug Administration (2026, August 10). Dissolution Methods Database, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/dissolution\/index.cfm."},{"key":"ref_45","first-page":"834173","article-title":"Stability Study of Darunavir Ethanolate Tablets Applying a New Stability-Indicating HPLC Method","volume":"2013","author":"Serra","year":"2013","journal-title":"Chromatogr. Res. Int."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Winck, J., Gottschalk, T., and Thommes, M. (2023). Predicting Residence Time and Melt Temperature in Pharmaceutical Hot Melt Extrusion. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15051417"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ponsar, H., Wiedey, R., and Quodbach, J. (2020). Hot-Melt Extrusion Process Fluctuations and Their Impact on Critical Quality Attributes of Filaments and 3D-Printed Dosage Forms. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060511"},{"key":"ref_48","unstructured":"United States Pharmacopeial Convention (2019). General Chapter <701> Disintegration. USP\u2013NF, United States Pharmacopeial Convention."},{"key":"ref_49","unstructured":"United States Pharmacopeial Convention (2020). General Chapter <731> Loss on Drying. USP\u2013NF, United States Pharmacopeial Convention."},{"key":"ref_50","unstructured":"United States Pharmacopeial Convention (2022). General Chapter <905> Uniformity of Dosage Units. USP\u2013NF, United States Pharmacopeial Convention."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.xphs.2022.04.004","article-title":"Comparison of Differential Scanning Calorimetry, Powder X-ray Diffraction, and Solid-state Nuclear Magnetic Resonance Spectroscopy for Measuring Crystallinity in Amorphous Solid Dispersions\u2014Application to Drug-in-Polymer Solubility","volume":"111","author":"Jarrells","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"ref_52","unstructured":"Merck KGaA (2022). Polyethylene Glycol 1500 for Synthesis, Product No. 807489; Product Specification\/Safety Data Sheet, Merck KGaA. Available online: https:\/\/www.sigmaaldrich.com\/US\/en\/product\/mm\/807489."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Tambe, S., Jain, D., Meruva, S.K., Rongala, G., Juluri, A., Nihalani, G., Mamidi, H.K., Nukala, P.K., and Bolla, P.K. (2022). Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102203"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.xphs.2024.06.020","article-title":"Long-Term Physical Stability of Amorphous Solid Dispersions: Comparison of Detection Powers of Common Evaluation Methods for Spray-Dried and Hot-Melt Extruded Formulations","volume":"114","author":"Kawakami","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1021\/acs.molpharmaceut.0c00918","article-title":"Characterization of Amorphous Solid Dispersions and Identification of Low Levels of Crystallinity by Transmission Electron Microscopy","volume":"18","author":"Blade","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.xphs.2022.10.020","article-title":"Detecting Crystallinity in Amorphous Solid Dispersions Using Dissolution Testing: Considerations on Properties of Drug Substance, Drug Product, and Selection of Dissolution Media","volume":"112","author":"Purohit","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1021\/acs.molpharmaceut.4c00342","article-title":"COSMOPharm: Drug\u2013Polymer Compatibility of Pharmaceutical Amorphous Solid Dispersions from COSMO-SAC","volume":"21","author":"Vrabec","year":"2024","journal-title":"Mol. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bhatta, H.P., Han, H.-K., Maharjan, R., and Jeong, S.H. (2025). Recent Techniques to Improve Amorphous Dispersion Performance with Quality Design, Physicochemical Monitoring, Molecular Simulation, and Machine Learning. Pharmaceutics, 17.","DOI":"10.20944\/preprints202508.0364.v1"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1021\/acs.molpharmaceut.4c01279","article-title":"Impact of Storage Conditions on the Physical Stability of Amorphous Solid Dispersions Containing Two Structurally Similar Drugs","volume":"22","author":"Jarrells","year":"2025","journal-title":"Mol. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s11095-025-03911-6","article-title":"Assessment of a Semi-Solid Extrusion Based Compounding System Solution for Personalized Ondansetron Dosage Forms Combined with Raman Spectroscopy Analysis","volume":"42","author":"Bahman","year":"2025","journal-title":"Pharm. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"106967","DOI":"10.1016\/j.ejps.2024.106967","article-title":"Automated Extrusion-Based Dispensing: Personalized Dosing and Quality Control of Clopidogrel Tablets for Pediatric Care","volume":"204","author":"Shokraneh","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Bernhardt, M.B., Shokraneh, F., Hrizanovska, L., Lahtinen, J., Brasher, C.A., and Sandler, N. (2025). Automated 3D Printing-Based Non-Sterile Compounding Technology for Pediatric Corticosteroid Dosage Forms in a Health System Pharmacy Setting. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17060762"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"107326","DOI":"10.1016\/j.ejps.2025.107326","article-title":"Hybrid GPP-Hospital Control Strategy for Semi-Solid Extrusion 3D Printing of ONC201 Chewable Units in Pediatric Oncology","volume":"216","author":"Ramos","year":"2026","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1079\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:49:04Z","timestamp":1787849344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":63,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091079"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091079","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}